Erasca
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Erasca sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Erasca: 8 sponsored US clinical trials, 2 recruiting.
Erasca sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced or Metastatic Solid Tumors, with 3 trials.
Upper-quartile sponsor footprint
Erasca sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
NCT07021898
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
NCT05039177
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04866134
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04670679
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
NCT04959981
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 3 | 1 |
What is open in the Erasca pipeline
2 recruiting of 8 indexed (25% open); 1 completed (13%).
Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Advanced or Metastatic Solid Tumors (3 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Erasca: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Erasca sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Erasca page
8 registered trials is a research-attention snapshot, not an endorsement of Erasca or any single study.
- 2 of Erasca's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced or Metastatic Solid Tumors is the condition Erasca studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced or Metastatic Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Erasca pipeline card: 8 registered trials from official public datasets.Report a data error.